Argireline vs Melanotan-1
A side-by-side research comparison of Argireline and Melanotan-1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Argireline | Melanotan-1 |
|---|---|---|
| Full name | Argireline (Acetyl Hexapeptide-3) | Melanotan-1 (Afamelanotide) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Approved (afamelanotide) / Research compound |
| Mechanism | Competes with SNAP-25 for position in SNARE complex, partially inhibiting vesicle docking and neurotransmitter release, reducing muscle contraction intensity. | Selectively activates the melanocortin-1 receptor (MC1R) on melanocytes, increasing eumelanin production and providing UV photoprotection and skin darkening. |
| Molecular weight | 889 Da | 1646.85 Da |
| Half-life | 8-12 hours (topical) | ~1 hour (peptide); implant form is sustained |
| Bioavailability | Moderate (topical) | Subcutaneous injection or sustained-release implant |
| Typical dose | 5-10% solution | ~0.5-1 mg per dose (research) |
| Frequency | 2x daily | Daily loading then maintenance |
| Route | Topical | Subcutaneous injection |
Argireline reported benefits
- Reduces expression wrinkles up to 30%
- Non-invasive Botox alternative
- Prevents new wrinkle formation
- No muscle paralysis
- Stackable with other peptides
Melanotan-1 reported benefits
- Skin tanning with less sun exposure
- UV photoprotection
- Fewer side effects than Melanotan-2
- Approved form for light-sensitivity disorder
Related comparisons
Research and educational reference only. Not medical advice.